-
Debate weighs whether BMI should remain central to obesity diagnosis
Francesco Rubino, MD, spoke in favor of moving beyond body mass index in diagnosing obesity. Leigh Perreault, MD, defended the long-time cornerstone of obesity diagnosis.
-
Session to address the economic and health value of obesity treatment
Panelists, including Tim Dall, MS, will help make business and social cases for investing in evidence-based treatment for obesity, such as lower healthcare costs, improved quality of life, and reduced mortality.
-
Obesity Year in Review to give an overview of major advances and discoveries
Presentations in this opening-day symposium will include a review of recent literature on the clinical application of glucagon-like peptide-1 (GLP-1)-based drugs by Julio E. Ayala, PhD, who will also identify knowledge gaps that can guide future clinical trials.
-
Presenter Profile: Age-Related Adipose Remodeling and Metabolic Dysfunction
Qiong Annabel Wang, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person 12:00 a.m., at 8:00 a.m. CT.
-
Presenter Profile: Roots of Inequity: In Utero Social and Environmental Impacts on Childhood Metabolic Risk
Izzuddin Aris, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Monday, June 8, at 8:00 a.m. CT.
-
Presenter Profile: Sexual Dimorphism in β-Cell Physiology and Susceptibility to Dysfunction
Emilyn Alejandro, PhD, previews a presentation at the 2026 Scientific Sessions. Attendees in New Orleans can watch the session in-person Saturday, June 6, at 8:00 a.m. CT.
-
Investigators to bring data on glucose management with oral orforglipron
Julio Rosenstock, MD, Francesco Giorgino, MD, PhD, and other panelists will discuss results from the ACHIEVE clinical trials, including ACHIEVE-3, which compared oral semaglutide and orforglipron for use in type 2 diabetes.
-
Experts to discuss the benefits of glucagon/GLP-1 receptor dual agonism gleaned from SYNCHRONIZE
Lee Kaplan, MD, PhD, and other investigators will examine the basic science underlying injectable survodutide, as well as results from two of the four studies in the SYNCHRONIZE program.
-
Session to provide updates on MASLD, lipoprotein biology, and CV risk
Panelists will discuss an underexplored nexus of metabolic dysfunction in diabetes on the final day of the 2026 Scientific Sessions. Scott Summers, PhD, will explore the role of ceramides in metabolic dysfunction-associated steatotic liver disease and cardiovascular risk. Other topics include cholesterol, clot lysis, and thrombosis.
-
Symposium to analyze amylin as novel therapy for diabetes and weight loss
W. Timothy Garvey, MD, and other researchers will share new insights from trials, such as REDEFINE, exploring long-acting amylin analogs as mono-agonists and in combination with agonists for other hormone receptors.